ARTICLE | Clinical News
Adempas riociguat regulatory update
April 7, 2014 7:00 AM UTC
The European Commission approved Adempas riociguat from Bayer to treat pulmonary arterial hypertension (PAH) and inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH...